Caspofungin acetate - Generic Drug Details

What are the generic sources for caspofungin acetate and what is the scope of patent protection?

Caspofungin acetate is the generic ingredient in two branded drugs marketed by Merck, Areva Pharms, Cipla, Fresenius Kabi Usa, Gland, Hangzhou Zhongmei, Hengrui Pharma, Pharmobedient, and Xellia Pharms Aps, and is included in nine NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Caspofungin acetate has fourteen patent family members in fourteen countries.

There are six drug master file entries for caspofungin acetate. Seven suppliers are listed for this compound.

Summary for caspofungin acetate

International Patents:	14
US Patents:	1
Tradenames:	2
Applicants:	9
NDAs:	9
Drug Master File Entries:	6
Finished Product Suppliers / Packagers:	7
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	20
Patent Applications:	973
Drug Prices:	Drug price trends for caspofungin acetate
What excipients (inactive ingredients) are in caspofungin acetate?	caspofungin acetate excipients list
DailyMed Link:	caspofungin acetate at DailyMed

See drug prices for caspofungin acetate

Recent Clinical Trials for caspofungin acetate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine	Phase 4
European Organisation for Research and Treatment of Cancer - EORTC	Phase 3
Children's Oncology Group	Phase 3

See all caspofungin acetate clinical trials

Pharmacology for caspofungin acetate

Drug Class

Echinocandin Antifungal

Anatomical Therapeutic Chemical (ATC) Classes for caspofungin acetate

J02AX	Other antimycotics for systemic use
J02A	ANTIMYCOTICS FOR SYSTEMIC USE
J02	ANTIMYCOTICS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

Paragraph IV (Patent) Challenges for CASPOFUNGIN ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CANCIDAS	for Injection	caspofungin acetate	50 mg/vial and 70 mg/vial	021227	1	2009-06-26

US Patents and Regulatory Information for caspofungin acetate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hangzhou Zhongmei	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	216506-001	Jul 18, 2025	AP	RX	No	No
Areva Pharms	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	211263-001	Oct 1, 2021	AP	RX	No	No
Merck	CANCIDAS	caspofungin acetate	POWDER;INTRAVENOUS	021227-001	Jan 26, 2001		DISCN	Yes	No
Gland	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	207092-002	Sep 29, 2017	AP	RX	No	No
Xellia Pharms Aps	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	205923-002	Jul 2, 2018		DISCN	No	No
Cipla	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	209489-002	Jul 12, 2018		DISCN	No	No
Hangzhou Zhongmei	CASPOFUNGIN ACETATE	caspofungin acetate	POWDER;INTRAVENOUS	216506-002	Jul 18, 2025	AP	RX	No	No

International Patents for caspofungin acetate

Country	Patent Number	Title	Estimated Expiration
Canada	2888625	COMPOSITIONS D'ACETATE DE CASPOFUNGINE (CASPOFUNGIN ACETATE FORMULATIONS)
Cyprus	1120016
Denmark	2922530
European Patent Office	2922530	COMPOSITIONS D'ACÉTATE DE CASPOFUNGINE (CASPOFUNGIN ACETATE FORMULATIONS)
Spain	2607646
Hong Kong	1215668	醋酸卡泊芬淨製劑 (CASPOFUNGIN ACETATE FORMULATIONS)
Croatia	P20161703

Supplementary Protection Certificates for caspofungin acetate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0620232	44/2001	Austria		PRODUCT NAME: CASPOFUNGIN, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE CASPOFUNGINACETAT; REGISTRATION NO/DATE: EU/01/196/001-003 20011024
0620232	2001/029	Ireland		PRODUCT NAME: CASPOFUNGIN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024; PAEDIATRIC INV. PLAN: P/30/2008
0620232	SPC/GB02/002	United Kingdom		A SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB02/002 GRANTED TO MERCK SHARP + DOHME, CORP IN RESPECT OF THE PRODUCT CASPOFUNGIN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY CASPOFUNGIN ACETATE, WHICH WAS ADVERTISED AS COMING INTO FORCE IN JOURNAL NO 5919 DATED 30 OCTOBER 2002 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, IT WILL EXPIRE ON 24 OCTOBER 2016.
0620232	C300076	Netherlands		PRODUCT NAME: CASPOFUNGINE, DESGEWENST IN DE VORM VAN EEN ZUURADDITIEZOUT, IN HET BIJZONDER CASPOFUNGINE ACETAAT; REGISTRATION NO/DATE: EU/1/01/196/001-003 20011024
0620232	01C0054	France		PRODUCT NAME: CASPOFUNGIN ACETATE; REGISTRATION NO/DATE: EU/1/01/196/001 20011024

Last updated: June 19, 2026

spoFUNGIN Acetate (Caspofungin): Market Dynamics and Financial Trajectory (U.S. and Global) CaspoFUNGIN acetate is an intravenous echinocandin antifungal used for invasive aspergillosis and other serious fungal infections. Revenue has transitioned from early growth to mature, steady demand with heightened exposure to label-loss and competitive substitution from other echinocandins and older antifungals. Financial trajectory is shaped by: (1) U.S. biosimilar/generic-era risks for caspofungin products, (2) hospital formulary decisions among echinocandins (micafungin, anidulafungin), (3) limited penetration outside hospital infusions and stewardship-driven use, and (4) supply and pricing dynamics for branded vs. authorized generic and fully generic presentations.

What drives the caspofungin acetate market: hospital demand, formulary access, and stewardship?

CaspoFUNGIN acetate sells into hospital inpatient and outpatient infusion settings where antifungal therapy is time-sensitive and protocol-driven. Demand is constrained by clinical guidelines that reserve echinocandins for high-risk patients and initial empiric therapy pathways, including neutropenia, stem cell transplant, and suspected invasive aspergillosis.

Key demand drivers

• Invasive aspergillosis treated volume: Use tracks incident rates and oncology hematology admission volumes.
• Empiric echinocandin placement: Many hospitals choose one echinocandin as default empiric therapy under antifungal stewardship policies.
• Drug budget pressure: Once a product becomes commercially interchangeable, hospitals often move to lowest-cost equivalent under contracting.

Key demand constraints

• Length of stay and dosing protocols: Caspofungin dosing schedules and duration requirements influence infused units per treated case.
• Switching among echinocandins: Patients can be switched mid-course, reducing “lock-in” to any one echinocandin for the full treatment timeline.
• Competition for formulary status: U.S. and EU tenders can shift market share quickly when acquisition or pricing changes occur.

How has caspofungin acetate revenue evolved over time in the U.S. and Europe?

CaspoFUNGIN acetate has followed a classic branded-to-mature transition. Growth early in lifecycle gave way to share pressure as echinocandin peers gained procurement leverage and as caspofungin moved toward generic competition. Post-entry of lower-priced versions typically shifts the revenue mix from branded to non-branded products, which reduces branded manufacturer net sales even if total market volume remains stable.

Revenue trajectory pattern (typical for mature IV antifungals)

• Branded peak era: Higher unit pricing and formulary coverage.
• Competitive normalization: Price compression after generic entry and contracting discounts.
• Ongoing stability with volatility: Quarterly sales can swing with:
  • hospital inventory cycles,
  • tender award dates,
  • supply disruptions affecting “available to promise,”
  • patient mix changes in oncology centers.

Which companies monetize caspofungin acetate and how does pricing power change after generic entry?

Market monetization shifts from the original branded manufacturer to a mix of branded partners (if any), authorized generics, and multiple generic firms once patents and exclusivity expire and ANDA approvals are available. Pricing power declines sharply after generic scale and competitive tendering.

Competitive structure likely to affect net sales

• Brand to generic mix shift: Total prescriptions and infusion use may stay consistent while branded net sales fall.
• Contracting dynamics: Hospital contracts often select one echinocandin for a budget segment, which redistributes volume across products.
• Authorized generic and supply: When authorized generic supply is robust, list-price economics matter less than net pricing to wholesalers and group purchasing organizations (GPOs).

What is caspofungin acetate’s financial trajectory linked to patent and exclusivity milestones?

Financial trajectory is driven by exclusivity ending and the timing of generic approvals, market entry, and any 180-day exclusivity incentives for first filers. For IV hospital drugs, even modest delays in market entry can hold up branded pricing, while rapid generic uptake can cut net sales materially.

Patent and exclusivity mechanisms that influence revenue

• Primary composition and method claims: Expiration opens ANDA pathway.
• Formulation and manufacturing method patents: Can delay “true” interchangeable generics if blocking patents are asserted.
• Exclusivity periods: Pediatric exclusivity or other statutory exclusivities (when applicable) can extend marketing protection past core patent terms.
• Paragraph IV litigation outcomes: Settlements can create “carve-outs” that delay generic launch or limit which strengths/NDCs launch.

How does caspofungin acetate compare with micafungin and anidulafungin in market share and pricing?

All three are echinocandins used in similar invasive fungal indications, which sets up direct competitive substitution in hospital formulary selection. Market share depends on:

• formulary position (preferred vs. alternative),
• contract pricing,
• IV infusion protocols,
• perceived tolerability and clinical comfort among prescribers,
• product availability.

Practical market outcome

• If one competitor secures preferred status in oncology centers and transplant programs, caspofungin volume tends to migrate to the preferred option.
• When generic caspofungin is available at a low net price, hospitals can re-introduce caspofungin as the cost-minimizing alternative, but only if contracting and logistics support it.

What is the “generic entry risk” for caspofungin acetate and how does it impact forecasted sales?

Generic entry risk is the dominant near-to-midterm driver of forecast changes for mature hospital injectables. Once at least one full-strength, approved generic is widely distributed, the typical effect is:

• steep first-wave price compression,
• reduced branded revenue,
• increased volatility from contract cycles rather than from patient incidence.

Forecast sensitivity points for caspofungin acetate

• ANDA approvals timing and rollout: Revenue impact depends on how quickly generics are stocked, allocated, and billed.
• NDC coverage: If generics launch only certain presentations, branded may hold residual share.
• Wholesaler inventory and shipment cycles: Short-term sales can swing based on stock timing rather than true demand shifts.
• Tender award re-bids: Contracts can reset pricing for 6 to 12 months in many institutional procurement systems.

What FDA status matters for market access and revenue for caspofungin acetate?

From a market dynamics perspective, FDA status influences:

• whether caspofungin presentations are directly substitutable,
• whether new generic entrants can be labeled “therapeutically equivalent,”
• how quickly pharmacists and hospitals switch at point of dispensing.

Orange Book listing dynamics that influence uptake

• Patent listings tied to specific NDCs: Determines launch feasibility for generics.
• Expiration sequencing: Even within the same active ingredient, different NDCs can have different patent/expiration dates.

What formulations and strengths affect uptake and financial results?

Caspofungin is administered IV, which makes logistics and clinical protocol adoption central. Market share is sensitive to:

• availability of the correct strength formats,
• compatibility with infusion workflows,
• pharmacy and nursing administration protocols.

Typical commercial sensitivities

• If a generic’s presentation aligns with hospital standard operating procedures, substitution is faster.
• If reconstitution or handling differs in a way that affects workflow, adoption can slow even if clinical interchangeability is established.

What litigation and settlement terms commonly alter caspofungin acetate revenue timelines?

For products in the mature echinocandin class, patent litigation outcomes and settlements can cause stepwise changes in revenue:

• Delay settlements reduce immediate generic competition, supporting branded net sales for an additional period.
• Scope-limited settlements can allow partial early entry by generics on non-blocked claims or specific strengths, keeping branded revenue higher than a full launch scenario.
• Adverse outcomes accelerate generic entry and intensify price compression.

What are the key global market dynamics for caspofungin acetate beyond the U.S.?

Outside the U.S., tender systems and reimbursement rules drive demand. In many EU markets:

• price regulation and reference pricing compress net pricing over time,
• hospital reimbursement constraints can increase generic substitution speed,
• country-by-country tender outcomes can shift competitive position.

What tends to repeat globally

• Equivalence substitution after patent expiry.
• Hospital-centric procurement and limited retail channel relevance.
• Echinocandin class competition where the “preferred drug” changes with contract cycles.

How do supply, manufacturing capacity, and distribution affect quarterly financial results?

For IV hospital drugs, supply reliability and distribution coverage materially influence recorded sales. Key issues include:

• manufacturing batch timing,
• ability to meet hospital demand forecasts during ramp-up,
• wholesaler allocation during supply constraints,
• distribution disruptions that can create temporary demand backlogs.

What it means for financial trajectory

• Sales can look weak during supply shortages because hospitals delay or substitute.
• Sales can spike after supply normalization due to catch-up ordering.

What does a realistic financial scenario analysis look like for caspofungin acetate?

A practical three-scenario model for mature IV antifungals typically uses:

1. Stable branded demand (slow substitution): branded net sales hold but shrink modestly.
2. Accelerated generic share shift (fast substitution): steep branded decline; total market revenue shifts to generics.
3. Contract-driven share swings: near-term volatility tied to tender timing.

Scenario markers to monitor

• Contract award announcements by large hospital systems
• Wholesaler inventory trends for caspofungin products
• New ANDA/generic launches by strength
• Litigation outcomes impacting specific NDCs

Key Takeaways

• CaspoFUNGIN acetate revenue has moved from branded growth into a mature hospital IV market where pricing power declines as generic and contracting pressures intensify.
• Financial trajectory is driven less by underlying incidence and more by formulary placement among echinocandins, contract cycles, and the timing/scope of generic entry.
• Competitive substitution against micafungin and anidulafungin is central to share and net price outcomes.
• Forecast risk clusters around generic rollout speed, NDC coverage, and any patent or settlement-driven delays.

FAQs

1) When does caspofungin acetate face the greatest generic price pressure in the U.S.?
After patent/exclusivity ending tied to specific NDCs and the first wave of ANDA distribution, branded net sales typically compress rapidly during the first tender cycles.

2) Do hospitals switch caspofungin to other echinocandins mid-treatment?
Yes. Switching can occur based on procurement contracts, clinical protocol preferences, tolerability considerations, and availability.

3) What tender factors most affect caspofungin acetate reimbursement and net pricing?
Preferred-drug selection, group purchasing organization terms, and reference price structures determine the net cost hierarchy among echinocandins.

4) How do supply constraints change observed sales for caspofungin acetate?
Shortages suppress billings and force substitutions, then can create catch-up demand once supply normalizes.

5) Which presentation-level issues most affect market uptake for IV caspofungins?
Strength coverage, handling and reconstitution workflow fit, and distribution readiness for pharmacy inventory management.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Reports and ANDA approvals database. U.S. Food and Drug Administration.
3. IQVIA Institute / industry antifungal market reporting (echinocandin class dynamics).
4. Company investor presentations and annual reports for echinocandin franchise and generic transition commentary.